OBJECTIVES: The high mortality among HIV/tuberculosis (TB) coinfected patients in Eastern Europe is partly explained by the high prevalence of drug-resistant TB. It remains unclear whether outcomes of HIV/TB patients with rifampicin/isoniazid-susceptible TB in Eastern Europe differ from those in Western Europe or Latin America. METHODS: One-year mortality of HIV-positive patients with rifampicin/isoniazid-susceptible TB in Eastern Europe, Western Europe, and Latin America was analysed and compared in a prospective observational cohort study. Factors associated with death were analysed using Cox regression models RESULTS: : Three hundred and forty-one patients were included (Eastern Europe 127, Western Europe 165, Latin America 49). Proportions of patients with disseminated TB (50, 58, 59%) and initiating rifampicin + isoniazid + pyrazinamide-based treatment (93, 94, 94%) were similar in Eastern Europe, Western Europe, and Latin America respectively, whereas receipt of antiretroviral therapy at baseline and after 12 months was lower in Eastern Europe (17, 39, 39%, and 69, 94, 89%). The 1-year probability of death was 16% (95% confidence interval 11-24%) in Eastern Europe, vs. 4% (2-9%) in Western Europe and 9% (3-21%) in Latin America; P < 0.0001. After adjustment for IDU, CD4 cell count and receipt of antiretroviral therapy, those residing in Eastern Europe were at nearly 3-fold increased risk of death compared with those in Western Europe/Latin America (aHR 2.79 (1.15-6.76); P = 0.023). CONCLUSIONS: Despite comparable use of recommended anti-TB treatment, mortality of patients with rifampicin/isoniazid-susceptible TB remained higher in Eastern Europe when compared with Western Europe/Latin America. The high mortality in Eastern Europe was only partially explained by IDU, use of ART and CD4 cell count. These results call for improvement of care for TB/HIV patients in Eastern Europe.
OBJECTIVES: The high mortality among HIV/tuberculosis (TB) coinfectedpatients in Eastern Europe is partly explained by the high prevalence of drug-resistant TB. It remains unclear whether outcomes of HIV/TBpatients with rifampicin/isoniazid-susceptible TB in Eastern Europe differ from those in Western Europe or Latin America. METHODS: One-year mortality of HIV-positivepatients with rifampicin/isoniazid-susceptible TB in Eastern Europe, Western Europe, and Latin America was analysed and compared in a prospective observational cohort study. Factors associated with death were analysed using Cox regression models RESULTS: : Three hundred and forty-one patients were included (Eastern Europe 127, Western Europe 165, Latin America 49). Proportions of patients with disseminated TB (50, 58, 59%) and initiating rifampicin + isoniazid + pyrazinamide-based treatment (93, 94, 94%) were similar in Eastern Europe, Western Europe, and Latin America respectively, whereas receipt of antiretroviral therapy at baseline and after 12 months was lower in Eastern Europe (17, 39, 39%, and 69, 94, 89%). The 1-year probability of death was 16% (95% confidence interval 11-24%) in Eastern Europe, vs. 4% (2-9%) in Western Europe and 9% (3-21%) in Latin America; P < 0.0001. After adjustment for IDU, CD4 cell count and receipt of antiretroviral therapy, those residing in Eastern Europe were at nearly 3-fold increased risk of death compared with those in Western Europe/Latin America (aHR 2.79 (1.15-6.76); P = 0.023). CONCLUSIONS: Despite comparable use of recommended anti-TB treatment, mortality of patients with rifampicin/isoniazid-susceptible TB remained higher in Eastern Europe when compared with Western Europe/Latin America. The high mortality in Eastern Europe was only partially explained by IDU, use of ART and CD4 cell count. These results call for improvement of care for TB/HIVpatients in Eastern Europe.
Authors: Jens D Lundgren; Abdel G Babiker; Fred Gordin; Sean Emery; Birgit Grund; Shweta Sharma; Anchalee Avihingsanon; David A Cooper; Gerd Fätkenheuer; Josep M Llibre; Jean-Michel Molina; Paula Munderi; Mauro Schechter; Robin Wood; Karin L Klingman; Simon Collins; H Clifford Lane; Andrew N Phillips; James D Neaton Journal: N Engl J Med Date: 2015-07-20 Impact factor: 91.245
Authors: D N Podlekareva; D Grint; F A Post; A Mocroft; A M Panteleev; R F Miller; J M Miro; M Bruyand; H Furrer; V Riekstina; E Girardi; M H Losso; J A Caylá; E A Malashenkov; N Obel; A M Skrahina; J D Lundgren; O Kirk Journal: Int J Tuberc Lung Dis Date: 2013-02 Impact factor: 2.373
Authors: Daria N Podlekareva; Anne Marie W Efsen; Anna Schultze; Frank A Post; Alena M Skrahina; Alexander Panteleev; Hansjakob Furrer; Robert F Miller; Marcelo H Losso; Javier Toibaro; Jose M Miro; Anna Vassilenko; Enrico Girardi; Mathias Bruyand; Niels Obel; Jens D Lundgren; Amanda Mocroft; Ole Kirk Journal: Lancet HIV Date: 2016-02-02 Impact factor: 12.767
Authors: Daria N Podlekareva; Joanne Reekie; Amanda Mocroft; Marcelo Losso; Aza G Rakhmanova; Elzbieta Bakowska; Igor A Karpov; Jeffrey V Lazarus; Jose Gatell; Jens D Lundgren; Ole Kirk Journal: BMC Infect Dis Date: 2012-09-25 Impact factor: 3.090
Authors: Yanink Caro-Vega; Anna Schultze; Anne Marie W Efsen; Frank A Post; Alexander Panteleev; Aliaksandr Skrahin; Jose M Miro; Enrico Girardi; Daria N Podlekareva; Jens D Lundgren; Juan Sierra-Madero; Javier Toibaro; Jaime Andrade-Villanueva; Simona Tetradov; Jan Fehr; Joan Caylà; Marcelo H Losso; Robert F Miller; Amanda Mocroft; Ole Kirk; Brenda Crabtree-Ramírez Journal: BMC Infect Dis Date: 2018-04-23 Impact factor: 3.090